Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
HK Stock MarketDetailed Quotes
INNOVENT BIO (01801)
- 90.000
- +5.100+6.01%
Market Closed Apr 30 16:07 CST
156.17BMarket Cap173.41P/E (TTM)
91.000High84.500Low18.45MVolume84.900Open84.900Prev Close1.64BTurnover1.06%Turnover Ratio173.41P/E (Static)1.74BShares109.10052wk High7.29P/B156.17BFloat Cap48.25052wk Low--Dividend TTM1.74BShs Float109.100Historical High--Dividend LFY7.66%Range %14.000Historical Low88.923Avg Price500Lot Size--Div Yield TTM--Div Yield LFY
INNOVENT BIO (01801) Income Statement
All
YOY
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 38.42%13.04B | 50.62%5.95B | 51.82%9.42B | 46.30%3.95B | 36.21%6.21B | 20.63%2.7B | 6.71%4.56B | 15.34%2.24B | 11.08%4.27B | 97.29%1.94B |
| Operating income | 38.42%13.04B | 50.62%5.95B | 51.82%9.42B | 46.30%3.95B | 36.21%6.21B | 20.63%2.7B | 6.71%4.56B | 15.34%2.24B | 11.08%4.27B | 97.29%1.94B |
| Cost of sales | -16.28%-1.76B | -23.01%-833.45M | -32.91%-1.51B | -34.27%-677.55M | -22.05%-1.14B | -7.02%-504.62M | -84.23%-930.99M | -117.42%-471.53M | -30.32%-505.34M | -17.35%-216.88M |
| Operating expenses | -16.28%-1.76B | -23.01%-833.45M | -32.91%-1.51B | -34.27%-677.55M | -22.05%-1.14B | -7.02%-504.62M | -84.23%-930.99M | -117.42%-471.53M | -30.32%-505.34M | -17.35%-216.88M |
| Gross profit | 42.64%11.29B | 56.34%5.12B | 56.05%7.91B | 49.06%3.27B | 39.84%5.07B | 24.26%2.2B | -3.69%3.63B | 2.50%1.77B | 8.92%3.76B | 115.77%1.72B |
| Selling expenses | -31.43%-5.71B | -26.38%-2.38B | -40.19%-4.35B | -39.48%-1.88B | -19.68%-3.1B | 3.61%-1.35B | 1.12%-2.59B | -28.93%-1.4B | -95.41%-2.62B | -142.76%-1.08B |
| Administrative expenses | -25.60%-926.98M | -38.25%-442.11M | 1.63%-738.05M | 13.19%-319.8M | 10.20%-750.28M | 9.66%-368.39M | -3.66%-835.49M | -32.46%-407.8M | -84.50%-806.01M | -64.78%-307.87M |
| Research and development expenses | 2.12%-2.62B | 27.91%-1.01B | -20.36%-2.68B | -51.65%-1.4B | 22.42%-2.23B | 21.43%-922.82M | -23.63%-2.87B | -20.54%-1.17B | -25.44%-2.32B | -20.59%-974.32M |
| Special items of operating profit | -770.09%-1.01B | -914.84%-311.72M | -211.98%-115.63M | -113.02%-30.72M | -106.14%-37.06M | -8.48%235.89M | 201.40%603.31M | 176.99%257.73M | 3.61%-594.98M | -578.42%-334.75M |
| Operating profit | 3,280.42%1.02B | 376.94%981.94M | 102.87%30.04M | -72.27%-354.57M | 49.45%-1.05B | 78.43%-205.82M | 19.79%-2.07B | 2.25%-954.35M | -226.34%-2.58B | -70.67%-976.3M |
| Financing cost | -17.67%-79.6M | -61.14%-61.26M | 31.41%-67.65M | 24.40%-38.02M | 3.02%-98.62M | -12.85%-50.29M | -62.81%-101.7M | -64.43%-44.57M | 8.61%-62.46M | 16.89%-27.1M |
| Share of profits of associates | -136.02%-96.79M | ---23.56M | ---41.01M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | 1,167.05%838.92M | 328.52%897.12M | 93.13%-78.62M | -53.29%-392.59M | 47.27%-1.14B | 74.36%-256.11M | 17.84%-2.17B | 0.45%-998.91M | -207.64%-2.64B | -65.94%-1B |
| Tax | -58.39%-25.36M | -179,317.14%-62.8M | -113.74%-16.01M | -100.03%-35K | 1,423.69%116.5M | 141.43%116.96M | 89.89%-8.8M | 31,971.05%48.44M | 37.70%-87.04M | 95.69%-152K |
| After-tax profit from continuing operations | 959.72%813.57M | 312.50%834.32M | 90.79%-94.63M | -182.16%-392.62M | 52.83%-1.03B | 85.36%-139.15M | 20.14%-2.18B | 5.29%-950.47M | -173.31%-2.73B | -65.01%-1B |
| Earning after tax | 959.72%813.57M | 312.50%834.32M | 90.79%-94.63M | -182.16%-392.62M | 52.83%-1.03B | 85.36%-139.15M | 20.14%-2.18B | 5.29%-950.47M | -173.31%-2.73B | -65.01%-1B |
| Profit attributable to shareholders | 959.72%813.57M | 312.50%834.32M | 90.79%-94.63M | -182.16%-392.62M | 52.83%-1.03B | 85.36%-139.15M | 20.14%-2.18B | 5.29%-950.47M | -173.31%-2.73B | -65.01%-1B |
| Basic earnings per share | 900.00%0.48 | 312.50%0.51 | 90.91%-0.06 | -166.67%-0.24 | 54.79%-0.66 | 86.15%-0.09 | 22.34%-1.46 | 5.80%-0.65 | -154.05%-1.88 | -50.00%-0.69 |
| Diluted earnings per share | 883.33%0.47 | 304.17%0.49 | 90.91%-0.06 | -166.67%-0.24 | 54.79%-0.66 | 86.15%-0.09 | 22.34%-1.46 | 5.80%-0.65 | -154.05%-1.88 | -50.00%-0.69 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | Deloitte Touche Tohmatsu会计师事务所 | -- | Deloitte Touche Tohmatsu会计师事务所 | -- | Deloitte Touche Tohmatsu会计师事务所 | -- | Deloitte Touche Tohmatsu会计师事务所 | -- | Deloitte Touche Tohmatsu会计师事务所 | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"